Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Inclusion Criteria: * Histologically proven metastatic/unresectable adrenocortical carcinoma or melanoma not amenable to curative surgical or radiation therapy. * Accrual closed as of 5/27/2009 to patients with renal cell carcinoma * No squamous cell histology * No histology in close proximity to a major blood vessel * No history of or known brain metastases, spinal cord compression, or carcinomatous meningitis * No new evidence of brain or leptomeningeal disease on screening CT scan or MRI * ECOG performance status (PS) 0-1 OR Karnofsky PS 60-100% * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * Creatinine ≤ 1.5 times ULN * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥100,000/mm³ * Hemoglobin ≥ 10.0 g/dL * Calcium ≤ 12.0 mg/dL * Urine protein:creatinine ratio ≤ 0.5 by urinalysis * Patients with urine protein:creatinine ratio \> 0.5 must have proteinuria \< 1,000 mg by 24-hour urine collection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy * None of the following within the past 12 months: * Myocardial infarction * Severe/unstable angina * Severe peripheral vascular disease (claudication) or procedure on peripheral vasculature * Coronary/peripheral artery bypass graft * New York Heart Association (NYHA) grade III-IV congestive heart failure * Cerebrovascular accident or transient ischemic attack * Clinically significant bleeding * Deep venous thrombosis * Pulmonary embolism * No ongoing cardiac dysrhythmias of NCI CTCAE ≥ grade 2, atrial fibrillation of any grade, or prolongation of the QTc interval to \> 450 msec (males) or \> 470 msec (females) * No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row) * No condition classified as NYHA grade III or IV * No hypertension that cannot be controlled by medications * Blood pressure \< 140/90 mm Hg * No evidence of bleeding diathesis or coagulopathy * No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No history of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening CT or MRI scan unless without progression on \* MRI or CT for 3 months." * No significant traumatic injury within the past 28 days * No serious, non-healing wound, ulcer, or bone fracture * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * No known HIV or AIDS-related illness * No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation. * Recovered from prior radiation therapy, surgery, or other prior therapy * No prior bevacizumab or sunitinib malate (SU11248) * Other antiangiogenic therapies allowed * No prior tyrosine kinase inhibitor of the VEGF receptor or bevacizumab for patients with metastatic renal cell carcinoma * No major surgical procedures or open biopsy within the past 28 days * No core biopsy within the past 7 days * No radiation therapy or systemic therapy within the past 4 weeks * No concurrent full-dose anticoagulants (e.g., warfarin) * Concurrent low-dose anticoagulation (e.g., prophylactic port patency) allowed * No concurrent treatment on another clinical trial * No other concurrent investigational drugs * No concurrent major surgery * No other concurrent anticancer agents or therapies, including chemotherapy, biological response modifiers, hormonal therapy, surgery, palliative radiation therapy, or immunotherapy